Antibody-drug conjugates (ADCs) are therapeutics that combine an antibody with a cytotoxic payload via a chemical linker to specifically target certain cells. Tumor-associated mucin-1 (TA-MUC1) is a glycosylated form of the MUC1 protein that is expressed in several cancer cells, thus being an interesting target for ADC development.
Incretin-based therapies have demonstrated substantial efficacy in the treatment of metabolic diseases such as obesity and type 2 diabetes but the need for frequent injections remains a major barrier to patient adherence and comfort.
The U.S. FDA has cleared Aavantgarde Bio Srl’s IND application for AAVB-039, the company’s gene therapy program for Stargardt disease, the most common inherited form of macular degeneration.
Acumen Pharmaceuticals Inc. and JCR Pharmaceuticals Co. Ltd. have entered a collaboration, option and license agreement to develop a novel therapeutic candidate for the treatment of Alzheimer’s disease (AD).
Palatin Technologies Inc. has announced preclinical results for PL-7737, an oral selective melanocortin MC4 receptor (MC4R) agonist, showing effectiveness in rodent models of obesity.
While people living with HIV can lead virtually normal lives thanks to antiretroviral therapy (ART), HIV persists in a latent state within cellular reservoirs that scientists do not know how to eliminate. “Transcription is a critical step in the viral life cycle. … But there are currently no drugs suppressing HIV transcription, and that may be one of the reasons why current antiretroviral therapy is not curative,” Melanie Ott told the audience at the 13th IAS Conference on HIV Science this week in Kigali, Rwanda.
Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease, cancer, atherosclerosis, metabolic dysfunction-associated steatohepatitis, respiratory and dermatological disorders.
AGC Inc. has synthesized compounds acting as prostaglandin E2 receptor EP4 subtype (PTGER4; EP4) antagonists reported to be useful for the treatment of cancer.
2A Biosciences Inc. has described phenethylamines acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric, neurodegenerative, neurodevelopmental, inflammatory and eye disorders.